CN114532544A - 降糖、控糖的谷果植物肽固体饮料 - Google Patents
降糖、控糖的谷果植物肽固体饮料 Download PDFInfo
- Publication number
- CN114532544A CN114532544A CN202210138510.XA CN202210138510A CN114532544A CN 114532544 A CN114532544 A CN 114532544A CN 202210138510 A CN202210138510 A CN 202210138510A CN 114532544 A CN114532544 A CN 114532544A
- Authority
- CN
- China
- Prior art keywords
- parts
- sugar
- solid beverage
- reducing
- plant peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
- 235000013361 beverage Nutrition 0.000 title claims abstract description 25
- 239000007787 solid Substances 0.000 title claims abstract description 25
- 230000002218 hypoglycaemic effect Effects 0.000 title claims description 7
- 235000000346 sugar Nutrition 0.000 claims abstract description 62
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 36
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 29
- 241000196324 Embryophyta Species 0.000 claims abstract description 26
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 16
- 239000001259 polydextrose Substances 0.000 claims abstract description 16
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 16
- 229940035035 polydextrose Drugs 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 244000062793 Sorghum vulgare Species 0.000 claims abstract description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 235000019713 millet Nutrition 0.000 claims abstract description 14
- 229920001184 polypeptide Polymers 0.000 claims abstract description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 14
- 229920001202 Inulin Polymers 0.000 claims abstract description 13
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 13
- 229940029339 inulin Drugs 0.000 claims abstract description 13
- 235000011194 food seasoning agent Nutrition 0.000 claims abstract description 12
- 235000021307 Triticum Nutrition 0.000 claims abstract description 11
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 11
- 229940001941 soy protein Drugs 0.000 claims abstract description 10
- 229940054810 white kidney bean extract Drugs 0.000 claims abstract description 10
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 8
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 dichloro sucrose Chemical compound 0.000 claims abstract description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005720 sucrose Substances 0.000 claims abstract description 8
- 239000000811 xylitol Substances 0.000 claims abstract description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 8
- 235000010447 xylitol Nutrition 0.000 claims abstract description 8
- 229960002675 xylitol Drugs 0.000 claims abstract description 8
- 239000004278 EU approved seasoning Substances 0.000 claims abstract description 7
- 240000002547 Rosa roxburghii Species 0.000 claims abstract description 7
- 235000000640 Rosa roxburghii Nutrition 0.000 claims abstract description 7
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 7
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 7
- 241000208340 Araliaceae Species 0.000 claims description 14
- 244000302512 Momordica charantia Species 0.000 claims description 12
- 241000209140 Triticum Species 0.000 claims description 10
- 235000013339 cereals Nutrition 0.000 claims description 7
- 241000220317 Rosa Species 0.000 claims description 5
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 4
- 235000018365 Momordica dioica Nutrition 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 229940071440 soy protein isolate Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 53
- 239000008280 blood Substances 0.000 abstract description 53
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 44
- 102000004877 Insulin Human genes 0.000 abstract description 22
- 108090001061 Insulin Proteins 0.000 abstract description 22
- 229940125396 insulin Drugs 0.000 abstract description 22
- 238000010521 absorption reaction Methods 0.000 abstract description 11
- 229920002472 Starch Polymers 0.000 abstract description 9
- 235000019698 starch Nutrition 0.000 abstract description 9
- 239000008107 starch Substances 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 8
- 238000000354 decomposition reaction Methods 0.000 abstract description 7
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 208000030159 metabolic disease Diseases 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 239000000284 extract Substances 0.000 abstract description 3
- 206010013663 drug dependence Diseases 0.000 abstract description 2
- 208000011117 substance-related disease Diseases 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 244000098338 Triticum aestivum Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000047 product Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 230000001276 controlling effect Effects 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000000291 postprandial effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 235000019710 soybean protein Nutrition 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003392 amylase inhibitor Substances 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003384 small molecules Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 235000009815 Momordica Nutrition 0.000 description 2
- 241000218984 Momordica Species 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 244000066764 Ailanthus triphysa Species 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000021278 navy bean Nutrition 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及代谢类疾病辅助调理领域,具体公开了降糖、控糖的谷果植物肽固体饮料。一种降糖、控糖的谷果植物肽固体饮料,由以下重量份的原料制备而成:大豆分离蛋白3~20份,苦瓜多肽1~10份,聚葡萄糖1~20份,菊粉1~20份,燕麦粉2~30份,人参果粉1~10份,白芸豆提取物1~10份,低聚木糖1~5份,小麦膳食纤维1~30份,刺梨1~10份。还包括以下重量份的调味料:L‑阿拉伯糖1份,二氯蔗糖1份,二氧化硅1份,木糖醇1份,硬脂酸镁1份。该谷果植物肽固体饮料配方选择食品提取物为主要原料,强化营养,俢复受损细胞,阻断淀粉的分解,减少糖的吸收,采用直接降糖的类植物胰岛素达到快速降糖,恢复血糖指标的目的,让更多糖尿病患者摆脱药物的依赖。
Description
技术领域
本发明涉及代谢类疾病辅助调理领域,特别涉及了药食同源的降糖、控 糖的谷果植物肽固体饮料的配方。
背景技术
治疗糖尿病的常见方案为服用降糖药物、皮下注射胰岛素、中药治疗等, 近年来也出现过一些设定类式营养调理的方法,但缺乏系统的理论支持,只 注重降糖,缺乏对病因的足够认识和理解,但没有解决代谢的根源问题(胰 岛素抵抗),这种治疗方法也是治标不治本,并且反弹率很高。
本申请所要解决的技术问题为:制备出一种以植物提取物为基础的原料, 强化营养、修复细胞、阻断淀粉的分解、减少对糖的吸收、提升人体的自愈 能力,达到恢复代谢功能,使血糖自然调节平衡的目的。
发明内容
为了克服现有技术的不足,本发明的目的在于提供一种药食同源、营养 价值高、调剂能力强的的降糖、控糖的谷果植物肽固体饮料。
本发明所采用的技术方案为:一种降糖、控糖的谷果植物肽固体饮料, 由以下重量份的原料制备而成:大豆分离蛋白3~20份,苦瓜多肽1~10份, 聚葡萄糖1~20份,菊粉1~20份,燕麦粉2~30份,人参果粉1~10份,白芸 豆提取物1~10份,低聚木糖1~5份,小麦膳食纤维1~30份,刺梨1~10份。
进一步的,所述的降糖、控糖的谷果植物肽固体饮料,由以下重量份的 原料制备而成:大豆分离蛋白5~10份,苦瓜多肽1~5份,聚葡萄糖3~10份, 菊粉3~10份,燕麦粉5~20份,人参果粉1~3份,白芸豆提取物1~3份,低 聚木糖1~3份,小麦膳食纤维3~10份,刺梨1~3份。
根据本发明的一种具体实施方式,所述的降糖、控糖的谷果植物肽固体 饮料,由以下重量份的原料制备而成:大豆分离蛋白7.5份,苦瓜多肽3份, 聚葡萄糖6.5份,菊粉6.5份,燕麦粉12.5份,人参果粉2份,白芸豆提取物 2份,低聚木糖2份,小麦膳食纤维8份,刺梨3份。
大豆分离蛋白具有降低血糖作用,大豆分离蛋白中的大豆肽对α-葡萄糖 苷酶有缓慢抑制作用,α-葡萄糖苷酶主要分布在肠微绒毛上,它的作用是迅 速分解糖供体内葡萄糖,因此大豆肽或与其它碳水化合物、糖类等物混合使 用时,不受胰岛素分泌量的影响,能起到抑制血糖急剧上升的作用,而且效 果很好。
苦瓜多肽中的植物胰岛素-苦瓜即苦瓜皂苷,在临床试验研究中表明苦瓜 皂苷连续服用3个月可增加糖尿病患者的胰岛素分泌,平衡血糖水平,同时 对糖尿病并发症如肾损伤,心功能受损等也有较好的作用。
白芸豆含α-淀粉酶抑制剂,能抑制α-淀粉酶的作用,阻断淀粉分解,减 少葡萄糖吸收,从而起到降低餐后血糖升高,减少胰岛素分泌,降低脂肪合 成等作用,可以有效配合糖尿病人和减肥者的饮食治疗,使他们饭吃饱、消 除饥饿感,而餐后血糖不高,体重不增,α-淀粉酶抑制剂通过降低α-淀粉酶 的活力,使食物中的淀粉分解速度降低,降低了餐后血糖高峰,减少了胰岛 素分泌量,在血糖管理和体重管理方面有重要应用。
刺梨中的黄酮能非常显著地降低小鼠的血清葡萄糖和甘油三酯,升高血 清胰岛素,使胰脏SOD和过氧化氢酶活性显著上升,丙二醇(MDA)明显下 降,从而具有保护胰脏、预防糖尿病的作用。
聚葡萄糖能改善末梢组织对胰岛素的感受性,降低对胰岛素的要求,抑 制胰岛素的分泌,阻碍对糖的吸收,且聚葡萄糖本身不被吸收,从而达到降 低血糖水平的目的,适用于糖尿病患者食用,聚葡萄糖相对血糖反应只有5~7, 而葡萄糖却有100。
菊粉在肠道的上部不会被水解成单糖,因而不会升高血糖水平和胰岛素 含量。
木糖醇在体内新陈代谢不需要胰岛素参与,不使血糖值升高,充当安全 甜味剂、营养补充剂和辅助治疗剂。
根据本发明的一种具体实施方式,所述的降糖、控糖的谷果植物肽固体 饮料,还包括以下重量份的调味料:L-阿拉伯糖1份,二氯蔗糖1份,二氧 化硅1份,木糖醇1份,硬脂酸镁1份。
L-阿拉伯糖能抑制水解双糖的酶,因此抑制因摄入蔗糖(在小肠蔗糖酶 的作用下分解成葡萄糖和果糖而被吸收)导致的血糖升高。
根据本发明的一种具体实施方式,所述大豆分离蛋白中蛋白质的含量至 少为90%,所述苦瓜多肽为脱色、脱味的白色粉末。
根据本发明的一种具体实施方式,所述人参果粉为人参果经低温提取得 到的小分子活性物质。
本发明降糖、控糖的谷果植物肽固体饮料的有益效果在于:
(1)、从白豆中提取的活力α-淀粉酶抑制剂对哺乳动物胰a-淀粉酶有较 强的抑制作用,通过抑制肠道内唾液及胰淀粉酶的活性,阻碍食物中淀粉及 其他碳水化合物的消化吸收,在不影响其它营养物质吸收和代谢的同时,选 择性地减少糖份摄取,减慢淀粉分解为单糖的速度,延缓单糖的消化吸收, 从而降低GI;
(2)、通过燕麦粉的高粘度延缓肠道对碳水化合物的吸收,使外源性血 糖降低,保护胰岛β细胞,修复其病变改善其功能特性使胰岛素得以保持稳 定的分泌达到调节血糖的目的,调节并激活PI3K胰岛素信号通路改善胰岛素 抵抗的状况;
(3)、用大豆蛋白代替膳食中的部分蛋白,不仅降低了胆固醇与饱和脂 肪的摄入量,同时也达到了营养摄取的均衡,有效阻止尿钙损失,促进骨质 健康,减少患骨质疏松的几率,并且辅助降低心血管类疾病的死亡率,有助 于增加肌力,增加肠道菌群的多样性;
(4)、通过以白芸豆提取物粉作为主要原料,再加入大豆肽粉、菊粉等 植物成分,阻断淀粉的分解、减少75%的糖分吸收,从而降低餐后血糖,提 升胰岛素敏感恢复调节功能,小分子还能轻松进入血管中,辅助疏通循环系 统,清除血管淤积的垃圾,更进一步地提高肝脏的代谢功能,帮助解酒、保 护肝脏,增加胰岛素的分泌,增强肝脏、脂肪组织的葡萄糖运输,达到降低 胆固醇、利尿去水肿功效,达到三层控糖的目的。
(5)、该谷果植物肽固体饮料配方选择食品提取物为主要原料,强化营 养,俢复受损细胞,阻断淀粉的分解,减少糖的吸收,采用直接降糖的类植 物胰岛素达到快速降糖,恢复血糖指标的目的,让更多糖尿病患者摆脱药物 的依赖。
附图说明
图1为本发明降糖、控糖的谷果植物肽固体饮料的对比试验一折线图;
图2为本发明降糖、控糖的谷果植物肽固体饮料的对比试验二折线图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行 清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而 不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做 出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
以下结合具体实施例对本发明作进一步详细描述,但本发明的实施方式 不限于此。
实施例1
一种降糖、控糖的谷果植物肽固体饮料,由以下重量份的原料制备而成: 大豆分离蛋白3份,苦瓜多肽1份,聚葡萄糖1份,菊粉1份,燕麦粉2份, 人参果粉1份,白芸豆提取物1份,低聚木糖1份,小麦膳食纤维1份,刺 梨1份。
还包括以下重量份的调味料:L-阿拉伯糖1份,二氯蔗糖1份,二氧化 硅1份,木糖醇1份,硬脂酸镁1份。
实施例2
一种降糖、控糖的谷果植物肽固体饮料,由以下重量份的原料制备而成: 大豆分离蛋白11.5份,苦瓜多肽5.5份,聚葡萄糖10.5份,菊粉10.5份,燕 麦粉16份,人参果粉5.5份,白芸豆提取物5.5份,低聚木糖3份,小麦膳 食纤维15.5份,刺梨5.5份。
还包括以下重量份的调味料:L-阿拉伯糖1份,二氯蔗糖1份,二氧化 硅1份,木糖醇1份,硬脂酸镁1份。
实施例3
一种降糖、控糖的谷果植物肽固体饮料,由以下重量份的原料制备而成: 大豆分离蛋白20份,苦瓜多肽10份,聚葡萄糖20份,菊粉20份,燕麦粉 30份,人参果粉10份,白芸豆提取物10份,低聚木糖5份,小麦膳食纤维 30份,刺梨10份。
还包括以下重量份的调味料:L-阿拉伯糖1份,二氯蔗糖1份,二氧化 硅1份,木糖醇1份,硬脂酸镁1份。
实施例4
一种降糖、控糖的谷果植物肽固体饮料,由以下重量份的原料制备而成: 大豆分离蛋白7.5份,苦瓜多肽3份,聚葡萄糖6.5份,菊粉6.5份,燕麦粉 12.5份,人参果粉2份,白芸豆水解蛋白2份,低聚木糖2份,小麦膳食纤 维8份,刺梨3份。
还包括以下重量份的调味料:L-阿拉伯糖1份,二氯蔗糖1份,二氧化 硅1份,木糖醇1份,硬脂酸镁1份。
实施例5
请参阅图1,取实施例四中的成品给患者食用,并分为每次食用0.5mmol/L 和1mmol/L,与未食用的患者进行对比,并记录其餐后180分钟内的血糖值 的变化,可从图1中看出,用餐后40分钟内血糖浓度都有所上升,其中,未 食用成品的患者血糖值达到了最高,约为16mmol/L,食用了0.5克成品的患 者血糖值较低,约为12mmol/L,食用了1克成品的患者血糖值最低,约为 10mmol/L,在40分钟至180分钟内时,患者的血糖值都进行下降,其中,在 180分钟时,未食用成品的患者血糖值仍最高,约为11mmol/L,食用了0.5 克成品的患者血糖值较低,约为9mmol/L,食用了1克成品的患者血糖值最 低,低于8mmol/L,由此可见,食用1克成品的患者的血糖浓度上升缓慢, 且下降速度快。
请参阅图2,取实施例四中的成品给患者食用,并分为每次食用0.5mmol/L 和1mmol/L,与未食用的患者进行对比,并记录其三天内的血糖值变化,可 从图2中看出,在第一天内患者的血糖浓度都有所下降,其中,未食用成品 的患者血糖值达到了最高,为16mmol/L,食用了0.5克成品的患者血糖值较 低,约为14mmol/L,食用了1克成品的患者血糖值最低,约为12mmol/L, 在第一天至第三天时,未食用成品的患者血糖值出现了升高,在第三天时已 经达到了约为15mmol/L,食用了0.5克成品的患者血糖值下降至了正常范围值以下,约为10mmol/L,食用了1克成品的患者血糖值最低,约为8mmol/L, 由此可见,食用成品的患者的血糖始终处于下降状态,且一直可以维持在标 准线以下,服用0.5克成品为最佳。
实施例6
取实施例四中的成品进行其中含有的营养成分的分析,分析结果如表一 所示:
项目 | 每100克(g) | NRV% |
能量 | 1604千焦(k) | 19% |
蛋白质 | 39.4克(g) | 66% |
脂肪 | 1.0克(g) | 2% |
碳水化合物 | 52.8克(g) | 18% |
钠 | 455毫克(mg) | 23% |
表一
糖尿病是失明、肾衰竭、心脏病的主要原因,据社会调研,每年有400 万人死于糖尿病,其中85%以上是二型糖尿病,有99%的糖尿病患者存在并 发症,15%患者视力下降甚至失明,16%糖尿病患者肾衰竭,50%糖尿病患者 死于心血管疾病,其还会造成脑血管病变、神经病变、眼睛病变、心血管病 变、皮肤病变、肾病变、微小血管病变和足部病变等。
因此,糖尿病患者只能依赖药物进行治疗,并且治疗通常伴随终生,也 就意味着患者需终生服药,市场上各常见的有关于控制血糖的药物基本上都 会存在副作用,也并不是每种人群都受用。
治疗糖尿病的药物通常有双胍类药物、磺酰基尿素类药物、甲型醣苷酶 抑制剂药物和直接注射胰岛素四种。
本发明针对常见的四种治疗药物的各类特性进行了分析,针对四种药物 的其主要作用、副作用和不适用人群分别进行了比对,四种药物的分析结果 如表二所示:
表二
由表二可得,双胍类药物会对患者的胃肠道造成不适,不适合肾功能不 全人群服用;磺酰基尿素药物会造成患者低血糖、腹部不适、头痛和过敏, 不适合孕妇及老年人、肝脏及肾脏功能不全者服用;甲型醣苷酶抑制剂药物 会造成患者肠胃不适,不适合肠炎患者服用;胰岛素会造成患者低血糖、脂 质代谢异常和过敏。
本发明药物采用了以食品提取物为主要成分,达到阻断淀粉的分解、减 少75%的糖分吸收,从而降低餐后血糖,提升胰岛素敏感恢复调节功能,小 分子的它还能轻松进入血管中,辅助疏通循环系统,清除血管淤积的垃圾, 更进一步地提高肝脏的代谢功能,帮助解酒、保护肝脏,增加胰岛素的分泌, 增强肝脏、脂肪组织的葡萄糖运输,促进胰岛素分泌、降低胆固醇、利尿去 水肿功效,达到三层控糖的目的,不会对患者造成更大痛苦,且并无不适用 人群。
本发明的规格为每盒15袋,每袋20克,呈白色粉末状,食用时以热水 冲泡后直接饮用。
实施例7
实际效果测试
选取患有代谢类疾病的患者,服用实施例四中的成品,并做身体各项指 标测试,测试结果如下表所示:
表三
表四
表五
表六
表七
由表三至表七可得,患有代谢类疾病的患者,都会出现不同程度的身体 水肿,导致超重,在服用实施例四的成品后,体重有明显下降,基本都维持 在正常体重范围内,并且血压和血糖都出现不同程度的下降,也基本维持在 正常范围内,患有糖尿病的患者,其注射胰岛素的单位也呈下降趋势,在服 用20至50天内,基本都不需注射胰岛素,靠自身胰岛素的生产即可调节自 身血糖的平衡。
Claims (6)
1.降糖、控糖的谷果植物肽固体饮料,其特征在于,由以下重量份的原料制备而成:大豆分离蛋白3~20份,苦瓜多肽1~10份,聚葡萄糖1~20份,菊粉1~20份,燕麦粉2~30份,人参果粉1~10份,白芸豆提取物1~10份,低聚木糖1~5份,小麦膳食纤维1~30份,刺梨1~10份。
2.根据权利要求1所述的降糖、控糖的谷果植物肽固体饮料,其特征在于,由以下重量份的原料制备而成:大豆分离蛋白5~10份,苦瓜多肽1~5份,聚葡萄糖3~10份,菊粉3~10份,燕麦粉5~20份,人参果粉1~3份,白芸豆提取物1~3份,低聚木糖1~3份,小麦膳食纤维3~10份,刺梨1~3份。
3.根据权利要求1所述的降糖、控糖的谷果植物肽固体饮料,其特征在于,由以下重量份的原料制备而成:大豆分离蛋白7.5份,苦瓜多肽3份,聚葡萄糖6.5份,菊粉6.5份,燕麦粉12.5份,人参果粉2份,白芸豆提取物2份,低聚木糖2份,小麦膳食纤维8份,刺梨3份。
4.根据权利要求1至3任意一项所述的降糖、控糖的谷果植物肽固体饮料,其特征在于,还包括以下重量份的调味料:L-阿拉伯糖1份,二氯蔗糖1份,二氧化硅1份,木糖醇1份,硬脂酸镁1份。
5.根据权利要求1所述的降糖、控糖的谷果植物肽固体饮料,其特征在于,所述大豆分离蛋白中蛋白质的含量至少为90%,所述苦瓜多肽为脱色、脱味的白色粉末。
6.根据权利要求1所述的降糖、控糖的谷果植物肽固体饮料,其特征在于,所述人参果粉为人参果经低温提取得到的小分子活性物质。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210138510.XA CN114532544A (zh) | 2022-02-15 | 2022-02-15 | 降糖、控糖的谷果植物肽固体饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210138510.XA CN114532544A (zh) | 2022-02-15 | 2022-02-15 | 降糖、控糖的谷果植物肽固体饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114532544A true CN114532544A (zh) | 2022-05-27 |
Family
ID=81675800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210138510.XA Withdrawn CN114532544A (zh) | 2022-02-15 | 2022-02-15 | 降糖、控糖的谷果植物肽固体饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114532544A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024013479A1 (en) * | 2022-07-10 | 2024-01-18 | Optibiotix Limted | Compositions and uses thereof |
-
2022
- 2022-02-15 CN CN202210138510.XA patent/CN114532544A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024013479A1 (en) * | 2022-07-10 | 2024-01-18 | Optibiotix Limted | Compositions and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108112996B (zh) | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 | |
CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
CN106261763A (zh) | 一种谷物膳食纤维代餐粉及其制备方法 | |
CN108850913A (zh) | 一种含益生元糖尿病特殊医学用途配方食品及其制备方法 | |
CN109221898A (zh) | 一种含低聚木糖的谷物粉及其制备方法和应用 | |
CN106038704A (zh) | 一种用于抑制食物消化吸收的组合物、制备方法及用途 | |
CN101234142A (zh) | 一种以辅助降血糖为主的桑系列保健功能性饮料 | |
CN104543834A (zh) | 一种具有降血糖功效的南瓜粉及其制备方法 | |
CN109939143A (zh) | 一种用于降血糖控制并发症的中药组合物及其制备方法 | |
CN112369577A (zh) | 一种阻糖美容组合物及其制备方法 | |
CN114532544A (zh) | 降糖、控糖的谷果植物肽固体饮料 | |
KR20100088794A (ko) | 새송이버섯 추출물을 유효성분으로 함유하는 제 2형 당뇨병에 의한 지질대사 장애 및 당뇨합병증 질환의 예방 및 치료용 조성물 | |
CN110624042B (zh) | 用于治疗糖尿性疾病的组合物 | |
CN113559150B (zh) | 一种蚕蛹-桑汁复合发酵制剂的制备方法及应用 | |
CN113796537B (zh) | 一种降糖组合物及其制作工艺 | |
JP2005213211A (ja) | 血糖値上昇抑制剤 | |
CN109700028A (zh) | 适用于肠型ⅰ人群的餐后血糖调节与预防的膳食组合物 | |
CN108887561A (zh) | 一种具有降血脂降血糖功效的代餐粉配方 | |
CN111214641B (zh) | 一种用于治疗糖尿病的中药制剂 | |
CN113397094A (zh) | 一种降脂降糖大豆蛋白粉及其制备方法 | |
CN105995971A (zh) | 一种促进糖尿病康复的营养流食及其制备方法 | |
KR101819920B1 (ko) | 항당뇨 및 항염증 활성을 갖는 꾸지뽕 추출물 함유 발효발아현미 조성물의 제조방법 | |
KR20080114456A (ko) | 홍경천을 이용한 항당뇨 복합조성물 | |
CN109198614A (zh) | 一种降低血糖食品的配方及其制备方法 | |
CN112335879A (zh) | 一种海红米皮制的控糖益生元及其制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220527 |